Standard therapies for  gastrointestinal cancers have proven to be effective, however patients with advance-stage disease have typically  a poor response   followed by a rapid progression. In the last  years, the concept and design of translational and clinical studies using biological agents  has been simplify by an increased understanding of the aberrant  signalling pathways regulating both the growth and the survival of cancer cells. The deeper knowledge  of molecular profiles of  different cancer subtypes and of treatment-resistant phenotypes will  improve therapeutic strategies. This symposium will present some of the emerging discoveries and latest treatment strategies which are currently under development. These studies might set a new paradigm in cancer treatment and may lead the way to develop future drugs.

Scheda di registrazione